![]() Friday 19th November 11am - 2pm The 2021 NCCRED Symposium will bring into focus three key areas of concern and innovation related to emerging drugs – Interventions, Networks & Pharmacotherapies. The symposium hosts leading national clinical researchers in the AoD field including presentations from recipients of NCCRED’s Round 3 Seed Funding Grants and the current work of the Centre. Areas of exploration in the 2021 symposium include:
Register now, its free Guest International PresenterDr. Madhukar TrivediMadhukar Trivedi, M.D., is a Professor of Psychiatry, Chief of the Division of Mood Disorders, and founding Director of the Center for Depression Research and Clinical Care at UT Southwestern Medical Center, where he holds the Betty Ho Hay Distinguished Chair in Mental Health and the Julie K. Hersh Chair for Depression Research and Clinical Care. Certified by the American Board of Psychiatry and Neurology, Dr. Trivedi focuses on developing and validating biosignatures of depression. He also conducts research on pharmacological, psychosocial, and nonpharmacological treatments for depression. He has been a principal investigator on numerous translational research projects and clinical trials. For More information including the full program visit our website New Real Drug Talk Podcast episode with NCCRED Director Nadine Ezard. The Real Drug Talk Podcast is hosted by NCCRED Working Group member Jack Nagle and discusses all things alcohol and drugs. It includes interviews with people with personal stories, family members that have had to deal with a loved ones alcohol or drug use, interesting experts in the space along with short tips and tricks to help anyone struggling with addictive patterns. The newest episode features NCCRED director Prof Nadine Ezard where they discuss some of the good things and some of the bad things about the alcohol and drugs sector as a whole. ![]() Real Drug Talk Podcast is available on all platforms and you can listen to it via Spotify here The National Centre for Clinical Research on Emerging Drugs is made up of a consortium of the following four institutions |